Researchers from Harvard Medical School and the Icahn School of Medicine at Mount Sinai found two rare, recurrent patterns of mutation in the post-mortem brain tissue of individuals with schizophrenia ...

H. Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing ...

Hologic Inc. signed an agreement to acquire Gynesonics Inc. for $350 million. The acquisition will significantly boost Hologic’s revenues from surgical gynecology and provide an option not met by the ...

Breast cancer cells, when disseminated to other secondary organs such as the lungs, may stay in a dormant state for years, even decades. But the mechanisms that limit their expansion are not well ...

The founding CEO of Alnylam Pharmaceuticals Inc. is now leading the charge with newly launched City Therapeutics Inc., which just completed a $135 million series A financing. City’s executive chair, ...

Following a slump in August, which posted the lowest med-tech deal values of 2024, September bounced back with the highest ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...

Keybioscience AG and Eli Lilly & Co. have agreed to extend their collaboration on the development of dual amylin and calcitonin receptor agonists (DACRAs), a new class of potential treatments for ...

Clinical research has shown that patients with systemic lupus erythematosus (SLE) are more likely to develop cardiovascular ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...

Booster Therapeutics is ready to open up a new arm of the proteasome after raising $15 million in seed funding to advance ...

Glooko Inc. secured a $100 million series F financing to support expansion of its diabetes ecosystem platform, which ...